Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Liabilities (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Total Liabilities data on record, last reported at $218.7 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 43.47% year-over-year to $218.7 million; the TTM value through Dec 2025 reached $218.7 million, up 43.47%, while the annual FY2025 figure was $218.7 million, 43.47% up from the prior year.
  • Total Liabilities reached $218.7 million in Q4 2025 per TARS's latest filing, up from $199.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $218.7 million in Q4 2025 and bottomed at -$202.6 million in Q3 2022.
  • Average Total Liabilities over 5 years is $58.9 million, with a median of $47.9 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: tumbled 2402.49% in 2021, then surged 202.44% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $12.2 million in 2021, then soared by 187.12% to $35.0 million in 2022, then soared by 95.93% to $68.5 million in 2023, then surged by 122.56% to $152.5 million in 2024, then soared by 43.47% to $218.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $218.7 million in Q4 2025, $199.5 million in Q3 2025, and $162.4 million in Q2 2025.